PE20212247A1 - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos - Google Patents

Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos

Info

Publication number
PE20212247A1
PE20212247A1 PE2021000924A PE2021000924A PE20212247A1 PE 20212247 A1 PE20212247 A1 PE 20212247A1 PE 2021000924 A PE2021000924 A PE 2021000924A PE 2021000924 A PE2021000924 A PE 2021000924A PE 20212247 A1 PE20212247 A1 PE 20212247A1
Authority
PE
Peru
Prior art keywords
substituted
alkyl
amino
unsubstituted
aminophenyl
Prior art date
Application number
PE2021000924A
Other languages
English (en)
Inventor
Massimo Ammirante
Sogoie Bahmanyar
Matthew D Correa
Virginia Grant
Joshua Hansen
Evan J Horn
Timothy S Kercher
Christopher Mayne
Mark A Nagy
Rama Krishna Narla
Surendra Nayak
Stephen Norris
Patrick Papa
Veronique Plantevin-Krenitsky
John J Sapienza
Brandon W Whitefield
Shuichan Su
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PE20212247A1 publication Critical patent/PE20212247A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La invencion se refiere a compuestos derivados de 3-((3-aminofenil)amino)piperidina-2,6-diona de formula (IA); en donde RN es H; cada R1 se selecciona de halogeno, CN y C1-3 alquilo; cada R2 y R3 se selecciona independientemente de H y C1-3 alquilo, o R2 y R3 y el carbono al que estan unidos forman un C3-6 cicloalquilo sustituido o no sustituido; cada R4 es C1-3 alquilo sustituido o no sustituido, o dos grupos R4, junto con el mismo atomo de carbono o atomo o atomos de carbono adyacentes a los que estan unidos, forman un C3-6 cicloalquilo sustituido o no sustituido, o dos grupos R4 junto con los atomos de carbono no adyacentes a los que estan unidos forman un heterociclilo de 4-7 miembros sustituido o no sustituido; X es N; L es -O(C1-6 alquilo)- o -(C1-9 alquilo)-; n es 0-4; m es 0-8. Un compuesto seleccionado es formiato de 2-(4-(2-(4-(3-(6-ciano-5-(trifluorometil)piridin-3-il)-5,5-dimetil-4- oxo-2-tioxoimidazolidin-1-il)fenoxi)etil)piperazin-1-il)-N-(3-((2,6-dioxopiperidin-3- il)amino)fenil)acetamida. Dichos compuestos son mediadores de los receptores androgenico (AR), siendo utiles para el tratamiento de enfermedades mediadas por AR, tal como el cancer de prostata.
PE2021000924A 2018-12-19 2019-12-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos PE20212247A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US201962879900P 2019-07-29 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
PE20212247A1 true PE20212247A1 (es) 2021-11-24

Family

ID=71098067

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000924A PE20212247A1 (es) 2018-12-19 2019-12-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos

Country Status (16)

Country Link
US (2) US11149007B2 (es)
EP (1) EP3897636A4 (es)
JP (1) JP2022514344A (es)
KR (1) KR20210118816A (es)
CN (1) CN113453681A (es)
AU (1) AU2019403207A1 (es)
BR (1) BR112021011968A2 (es)
CA (1) CA3124130A1 (es)
CL (1) CL2021001665A1 (es)
CO (1) CO2021007973A2 (es)
IL (1) IL284223A (es)
MX (1) MX2021007473A (es)
PE (1) PE20212247A1 (es)
SG (1) SG11202106507RA (es)
TW (1) TWI820276B (es)
WO (1) WO2020132014A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210118816A (ko) * 2018-12-19 2021-10-01 셀진 코포레이션 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
BR112021012186A2 (pt) 2018-12-19 2021-08-31 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
TW202216690A (zh) 2020-06-24 2022-05-01 美商西建公司 Ｃｅｒｅｂｌｏｎ結合化合物、其組合物及使用該等物質之治療方法
CA3182325A1 (en) 2020-06-24 2021-12-30 Matthew D. Alexander Cereblon binding compounds, compositions thereof, and methods of treatment therewith
AR122725A1 (es) * 2020-06-24 2022-09-28 Celgene Corp Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
AU2021402911A1 (en) 2020-12-14 2023-07-06 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117545752A (zh) * 2021-06-25 2024-02-09 细胞基因公司 Cereblon结合化合物、其组合物及其用于治疗的方法
EP4359407A1 (en) * 2021-06-25 2024-05-01 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CA2579886A1 (en) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007136640A2 (en) * 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CN102510755A (zh) 2009-07-13 2012-06-20 哈佛大学校长及研究员协会 双功能钉接多肽和其用途
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
WO2012135284A2 (en) 2011-03-28 2012-10-04 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
MX368844B (es) * 2012-09-04 2019-10-16 Shanghai hengrui pharmaceutical co ltd Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9139529B2 (en) 2013-01-31 2015-09-22 Vertex Pharmaceuticals Incorporated Substituted quinoxalines as sodium channel modulators
JP6778114B2 (ja) 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3256470B1 (en) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2018000360A (es) 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (zh) * 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3481394A1 (en) * 2016-07-08 2019-05-15 Janssen Pharmaceutica N.V. Thiohydantoin androgen receptor antagonists for the treatment of cancer
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
AU2017341723B2 (en) 2016-10-11 2021-12-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
RU2747260C2 (ru) 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
MX2019009046A (es) 2017-01-31 2019-10-30 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que comprenden el mismo.
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 ***癌治疗药物
WO2019106691A1 (en) 2017-11-28 2019-06-06 Aarti Industries Limited Process for preparation of enzalutamide using novel intermediate
WO2019113006A1 (en) 2017-12-05 2019-06-13 Dow Agrosciences Llc Pesticidal compositions and methods
JP7456945B2 (ja) 2018-05-30 2024-03-27 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 三環式誘導体を含む阻害剤、その製造方法、及び使用
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
BR112021012186A2 (pt) * 2018-12-19 2021-08-31 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
KR20210118816A (ko) * 2018-12-19 2021-10-01 셀진 코포레이션 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법

Also Published As

Publication number Publication date
EP3897636A4 (en) 2022-09-07
US20230002321A1 (en) 2023-01-05
WO2020132014A1 (en) 2020-06-25
AU2019403207A1 (en) 2021-07-15
KR20210118816A (ko) 2021-10-01
CA3124130A1 (en) 2020-06-25
MX2021007473A (es) 2021-08-05
JP2022514344A (ja) 2022-02-10
TWI820276B (zh) 2023-11-01
US20200199073A1 (en) 2020-06-25
CL2021001665A1 (es) 2022-01-14
IL284223A (en) 2021-08-31
CN113453681A (zh) 2021-09-28
BR112021011968A2 (pt) 2021-09-08
SG11202106507RA (en) 2021-07-29
US11149007B2 (en) 2021-10-19
TW202039435A (zh) 2020-11-01
US11873283B2 (en) 2024-01-16
EP3897636A1 (en) 2021-10-27
CO2021007973A2 (es) 2021-09-09

Similar Documents

Publication Publication Date Title
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
PE20190409A1 (es) Compuesto heterociclico
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
PE20181449A1 (es) Compuestos utiles como inhibidores de cinasa
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
TR201909160T4 (tr) Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
PE20160995A1 (es) Inhibidores de syk
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20131143A1 (es) Nuevas aminopirazoloquinazolinas
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
RS54288B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
BR112016019462B8 (pt) Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase